HomeCompareKNBIF vs EQR

KNBIF vs EQR: Dividend Comparison 2026

KNBIF yields 9090.91% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KNBIF wins by $21569447714287804.00M in total portfolio value
10 years
KNBIF
KNBIF
● Live price
9090.91%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21569447714287804.00M
Annual income
$21,112,599,253,241,626,000,000.00
Full KNBIF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — KNBIF vs EQR

📍 KNBIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKNBIFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KNBIF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KNBIF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KNBIF
Annual income on $10K today (after 15% tax)
$772,727.27/yr
After 10yr DRIP, annual income (after tax)
$17,945,709,365,255,380,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, KNBIF beats the other by $17,945,709,365,255,380,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KNBIF + EQR for your $10,000?

KNBIF: 50%EQR: 50%
100% EQR50/50100% KNBIF
Portfolio after 10yr
$10784723857143902.00M
Annual income
$10,556,299,626,620,813,000,000.00/yr
Blended yield
97.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

KNBIF
No analyst data
Altman Z
-21.3
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KNBIF buys
0
EQR buys
0
No recent congressional trades found for KNBIF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKNBIFEQR
Forward yield9090.91%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$21569447714287804.00M$40.5K
Annual income after 10y$21,112,599,253,241,626,000,000.00$3,819.61
Total dividends collected$21538997001133020.00M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: KNBIF vs EQR ($10,000, DRIP)

YearKNBIF PortfolioKNBIF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$919,791$909,090.91$11,248$547.57+$908.5KKNBIF
2$79,131,237$78,147,061.10$12,701$666.53+$79.12MKNBIF
3$6,367,969,272$6,283,298,848.49$14,405$814.59+$6367.95MKNBIF
4$479,373,708,687$472,559,981,565.83$16,413$999.84+$479373.69MKNBIF
5$33,759,466,880,937$33,246,537,012,641.96$18,795$1,232.92+$33759466.86MKNBIF
6$2,224,307,476,184,878$2,188,184,846,622,275.00$21,639$1,527.95+$2224307476.16MKNBIF
7$137,120,917,193,402,000$134,740,908,193,884,210.00$25,057$1,903.80+$137120917193.38MKNBIF
8$7,909,629,907,685,076,000$7,762,910,526,288,135,000.00$29,197$2,385.87+$7909629907685.05MKNBIF
9$426,961,178,547,826,460,000$418,497,874,546,603,460,000.00$34,250$3,008.70+$426961178547826.38MKNBIF
10$21,569,447,714,287,803,000,000$21,112,599,253,241,626,000,000.00$40,467$3,819.61+$21569447714287804.00MKNBIF

KNBIF vs EQR: Complete Analysis 2026

KNBIFStock

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Full KNBIF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this KNBIF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KNBIF vs SCHDKNBIF vs JEPIKNBIF vs OKNBIF vs KOKNBIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.